| Hazard Information | Back Directory | [Uses]
SHEN26 (ATY014) is a potent and orally active RdRp inhibitor, with an IC50 for SARS-CoV-2 is 1.36 μM. SHEN26 is a 5’-cyclohexanecarboxylate derivative of GS-441524 (HY-103586). SHEN26 inhibits viral nucleic acid synthesis to achieve antiviral effects. SHEN26 can be used for the research of
coronavirus disease 2019 (COVID-19)[1][2]. | [References]
[1] Chen Q, et al. Optimized Kilogram-Scale Synthesis and Impurity Identification of SHEN26 (ATV014) for Treating COVID-19. Organic Process Research & Development. 2023 Nov 20.
[2] Ji X, et al. Research and development of Chinese anti-COVID-19 drugs. Acta Pharm Sin B. 2022 Dec;12(12):4271-4286. DOI:10.1016/j.apsb.2022.09.002 |
|
|